Regadenoson in the detection of coronary artery disease

Vascular Health and Risk Management

Volumn 4, Issue 2, 2008, Pages 337-340

  Buhr, Christiane ^a   Gössl, Mario ^b   Erbel, Raimund ^a   Eggebrecht, Holger ^a  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

^b Mayo Clinic   (United States)

Author keywords

Adenosine; Coronary vasodilation; Physical exercise; Regadenoson; Selective A2A adenosine receptor agonism; Ultrashort lasting adenosine receptor stimulation

Indexed keywords

2 [4 (2 CARBOXYETHYL)PHENETHYLAMINO]ADENOSINE 5' (N ETHYLCARBOXAMIDE); ADENOSINE; ADENOSINE A2 RECEPTOR AGONIST; ADENOSINE DERIVATIVE; BINODENOSON; CVT 2995; CVT 3032; CVT 3033; REGADENOSON;

ABDOMINAL PAIN; ATRIOVENTRICULAR BLOCK; BRAIN BLOOD FLOW; BRONCHOSPASM; CLINICAL TRIAL; CORONARY ARTERY DILATATION; CORONARY ARTERY DISEASE; DIAGNOSTIC IMAGING; DIZZINESS; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG SYNTHESIS; DYSPNEA; FLUSHING; GASTROINTESTINAL SYMPTOM; HEART MUSCLE ISCHEMIA; HEART MUSCLE PERFUSION; HUMAN; HYPEREMIA; HYPOTENSION; PHARMACOLOGIC STRESS TESTING; REVIEW; SIDE EFFECT; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS; TACHYCARDIA; THORAX PAIN;

ANIMALS; CORONARY ARTERY DISEASE; CORONARY CIRCULATION; CORONARY VESSELS; HEART FUNCTION TESTS; HUMANS; HYPEREMIA; PURINES; PYRAZOLES; RECEPTOR, ADENOSINE A2A; STRUCTURE-ACTIVITY RELATIONSHIP; TIME FACTORS; VASODILATION; VASODILATOR AGENTS;

EID: 44049095960     PISSN: 11766344     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (15)

1. Baghdasarian SB, Heller GV. 2005. The role of myocardial perfusion imaging in the diagnosis of patients with coronary artery disease: developments over the past year. Curr Opin Cardiol, 20:369-74.
2. Belardinelli L, Shryock JC, Ruble J, et al. 1996. Binding of the novel nonxanthine A2A adenosine receptor antagonist [3H]SCH58261 to coronary artery membranes. Circ Res, 79:1153-60.
3. Cerqueira MD. 2004. The future of pharmacologic stress: selective A2A adenosine receptor agonists. Am J Cardiol, 94:33D-40D (472226).
4. Cerqueira MD, Verani MS, Schwaiger M, et al. 1994. Safety profile of adenosine stress perfusion imaging: results from the Adenoscan Multicenter Trial Registry. J Am Coll Cardiol, 23:384-9.
5. CV Therapeutics, Inc. 2005a. Astellas and CV's regadenoson comparable to Adenoscan in heart imaging study [press release] August 10, 2005.
6. CV Therapeutics, Inc. 2005b. Regadenoson Phase 3 Data Presented as Late-Breaker at American Society of Nuclear Cardiology [press release]. October 2, 2005.
7. Hendel RC, Mahmarian JJ, Bateman TM, et al. 2004. Initial results regarding safety, tolerability, and hemodynamic effects of CVT-3146, a Selective Adenosine A2A receptor agonist, in patients undergoing pharmacologic stress SPECT myocardial perfusion imaging abstract. J Am Coll Cardiol, 43:367A.
8. Hendel RC, Mahmarian JJ, Cerqueira MD et al. 2003. Pharmocologic stress SPECT myocardial perfusion imaging with a selective A2A agonist: results of a pilot study comparing adenosine with CVT-3146 [abstract]. Circulation, 108:17.
9. Gao Z, Otero DH, Zablocki JA, et al. 2000. Pharmacological characterization of novel A2A adenosine receptor (A2AAdoR) agonists. Drug Dev Res, 50:93.
10. Kerensky RA, von Mering GO, Kent KM, et al. 2002. Dose dependent increase in human coronary blood flow velocity after an iv bolus of CVT-3146, a novel A2A adenosine receptor agonist: a potential agent for the use in pharmacological stress testing for myocardial perfusion imaging [abstract]. Circulation, 106:618.
11. Palle V, Elzein E, Gothe SA, et al. 2000. Design, synthesis and pharmacological evaluation of 2(1-alkyl-pyrazol-4-yl) adenosine derivatives as short acting adenosine A2A receptor agonists. Drug Dev Research, 50:64.
12. Palle VP, Elzein EO, Gothe SA, et al. 2002. Structure-affinity relationships of the affinity of 2-pyrazolyl adenosine analogues for the adenosine A2A receptor. Bioorg Med Chem Lett, 12:2935-9.
13. Ranhosky A, Kempthorne-Rawson J. 1990. The safety of intravenous dipyridamole thallium myocardial perfusion imaging. Intravenous Dipyridamole Thallium Imaging Study Group. Circulation, 81:1205-9.
14. Zablocki J, Palle V, Blackburn B, et al. 2000. Novel short acting coronary vasodilators that are functionally selective for the A2A receptor based on 2-heterocyclic substituted adenosine derivatives. Drug Dev Res, 50:63.
15. Zablocki J, Palle V, Blackburn B, et al. 2001. 2-substituted pi system derivatives of adenosine that are coronary vasodilators acting via the A2A adenosine receptor. Nucleosides Nucleotides Nucleic Acids, 20:343-60.